2018
DOI: 10.1016/j.cardfail.2018.01.011
|View full text |Cite
|
Sign up to set email alerts
|

Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device

Abstract: Background Recurrent gastrointestinal bleeding is one of the most significant adverse events in patients with left ventricular assist devices (LVAD). Methods We enrolled LVAD patients who had received an intramuscular injection of 20 mg of octreotide LR every 4 weeks as secondary prevention for recurrent gastrointestinal bleeding despite conventional medical therapies and repeated transfusions. The frequency of gastrointestinal bleeding and other associated clinical outcomes before and during octreotide ther… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
29
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 31 publications
(29 citation statements)
references
References 24 publications
0
29
0
Order By: Relevance
“…11,20 Other therapies, such as danazol and thalidomide, have recently been proposed for the management of GIB. 21,22 However, their clinical use may be restricted to the secondary prevention of GIB, considering their significant adverse effect profiles.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…11,20 Other therapies, such as danazol and thalidomide, have recently been proposed for the management of GIB. 21,22 However, their clinical use may be restricted to the secondary prevention of GIB, considering their significant adverse effect profiles.…”
Section: Discussionmentioning
confidence: 99%
“…In cases of recurrent bleeding, patients were started on long-acting octreotide as an outpatient, 11 and in select cases, the INR target was reduced.…”
Section: Methodsmentioning
confidence: 99%
“…Several strategies have been suggested for preventing and reducing gastrointestinal bleeding, which may increase the amount of uninterrupted therapy with warfarin and aspirin, and decrease thromboembolic events. Octreotide injections can help to prevent re‐bleeding, which may allow for warfarin and aspirin to be given continuously following the index gastrointestinal bleed 26 . Also, routine therapy with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) has been shown to reduce GIB by 57% 42 .…”
Section: Discussionmentioning
confidence: 99%
“…Bleeding, particularly gastrointestinal bleeding, is among the most common comorbidities during LVAD support with an estimated incidence of 25% [24]. Some gastrointestinal bleeding events are refractory to all available therapeutic strategies including octreotide, danazol, and thalidomide in addition to the termination of antiplatelet and anticoagulation therapies [25].…”
Section: Gastrointestinal Bleedingmentioning
confidence: 99%